Skip to main content
. Author manuscript; available in PMC: 2022 Jan 20.
Published in final edited form as: J Allergy Clin Immunol. 2021 Oct;148(4):953–963. doi: 10.1016/j.jaci.2021.08.013

TABLE I.

Currently approved JAK inhibitors for various indications

Compound Indication
Tofacitinib RA, PsA, UC
Ruxolitinib PCV, MF
Baricitinib RA
Upadacitinib RA
Fedratinib MF

MF, Myelofibrosis; PCV, polycythemia vera; PsA, psoriatic arthritis; UC, ulcerative colitis.